CPA
LGND icon

Capital Performance Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Capital Performance Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-17
Closed -$1.7K – 1537
2024
Q3 		$1.7K Buy
+17
New +$1.71K ﹤0.01% 1647

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Performance Advisors's LGND Position: Q4 2024 in Review

Capital Performance Advisors sold out of Ligand Pharmaceuticals (LGND) in Q4 2024, closing a stake of 17 shares — an estimated $1.7K sold.

Capital Performance Advisors first reported a position in LGND in Q3 2024 and held it in 1 quarter. The position peaked at $1.7K in Q3 2024. 258 funds tracked by Wall St. Rank hold LGND as of Q4 2024.

  • Capital Performance Advisors reported no remaining Ligand Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 17 Ligand Pharmaceuticals shares in Q4 2024, an estimated $1.7K.
  • Capital Performance Advisors first reported a position in Ligand Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Ligand Pharmaceuticals position peaked at $1.7K in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.